Harmonic Pharma at the 10th annual meeting of the American Society for Cellular and Computational Toxicology, October 12-14, 2021

13 October 2021

Harmonic Pharma attended the annual meeting of the ASCCT : click here to read our poster.

Adebiotech Webinar

27 June 2021

Our CSO Sinan Karaboga will be giving a presentation, In Silico Predictive Toxicology: Genotoxic Impurities Case Study, during the webinar on detection, prediction and analysis of mutagenic/genotoxic compounds hosted by Adebiotech on July 1st. All the details here !


Webinar Clubster NSL

26 April 2021

Clubster NSL | LinkedIn

Our scientific director will attend the webinar from Clubster NSL on april 28th.

Inria article

23 April 2021

Learn more about Harmonic Pharma in the last article from INRIA here (french version here).

New partnership

24 April 2021

Harmonic Pharma is involved in a new partnership, alongside with Seqens and Genevolution, aiming at the development of a control strategy for Genotoxic Impurities (GTI’s). All details here.

Harmonic Pharma HPH561 and COVID-19 : Synopsis

15 April 2021

HPH561 – a drug originally developed as an antifungal agent – was selected and revisited through the proprietary Harmonic Rediscovery platform. The resulting polypharmacology profile revealed an ensemble of biomolecular targets shared with haloperidol and clemastine, two repurposed drug candidates for COVID-19 treatment. Thus, HPH561 was tested against SARS-CoV-2 in an in vitro assay and showed a consistent antiviral activity.

Furthermore, the polypharmacological profile of HPH561 pointed out a biomolecular target involved in dampening inflammation as well as lung permeability and pulmonary edema.

At the cellular level, HPH561 has shown a lysosomotropism that is assumed to lead to a significant decrease in viral load or no SARS-CoV-2 infection of airway epithelial cells.

In addition, it has been reported that HPH561 shows a high affinity for SARS-CoV-2 papain-like protease (PLpro) – an essential coronavirus enzyme that is required for processing viral polyproteins to generate a functional replicase complex and enable viral spread.

Altogether, the current biological properties associated with HPH561 make this repurposed drug a potential candidate of high interest to treat COVID-19.

Read our official press release.

************ French Version ************

HPH561, un principe actif antifongique à l’origine, a fait l’objet d’une sélection et d’une caractérisation via notre plateforme technologique « Rediscovery ». Le profil polypharmacologique qui en a résulté révèle un ensemble de cibles biologiques associées à HPH561 dont certaines sont communes avec celles de l’haloperidol et la clemastine, deux principes actifs candidats repositionnés pour le traitement de la COVID-19. Ainsi, HPH561 a fait l’objet d’un test in vitro contre SARS-CoV-2 et a montré une activité antivirale.

En outre, le profil polypharmacologique de HPH561 a mis en évidence une cible biologique impliquée dans la réduction de l’inflammation ainsi que de la perméabilité et l’œdème pulmonaires.

Au niveau cellulaire, HPH561 montre un tropisme lysosomal qui est considéré conduire à une diminution de la charge virale ou une absence d’infection au SARS-CoV-2 dans les cellules épithéliales des voies aériennes.

De plus, des études ont montré que HPH561 avait une affinité forte pour la protéase « SARS-CoV-2 papain like » (PLpro), une enzyme essentielle du coronavirus qui est requise pour la production de protéines virales afin d’obtenir un complexe de réplication fonctionnel et une propagation du virus.

En résumé, les propriétés biologiques associées à HPH561 font de ce principe actif repositionné un potentiel candidat d’un intérêt certain pour traiter la COVID-19.

Notre communiqué de presse officiel est disponible ici.

Offre d'emploi

10 December 2020

Dans le cadre de notre partenariat avec le LORIA (Laboratoire Lorrain de Recherche en Informatique et ses Applications), nous recherchons un ingénieur Bio/Chimio-informaticien.

Plus d’informations ici.

Safety by design® : a new approach on toxicological risk assessment

1 December 2020


Harmonic Pharma, hosted in the startup area of Mines Nancy, launched in October 2019 the Chemical Range ® program dedicated to toxicological risks, in partnership with the LORIA laboratory. This dual innovation program for civil and military purposes embodies the Safety by design ® approach. Learn more with our french press release here.

IAR Work Group

9 November 2020
IAR Work Group

CSO Arnaud Sinan Karaboga will give a presentation during the IAR Work group on November 19th : « Safety by design ® »: a new approach to balance efficacy and safety during compound development using Artificial intelligence (AI) techniques”. All information here.

CNRS united against Coronavirus

10 April 2020
CNRS united against Coronavirus

Harmonic Pharma works with the Loria (Lorraine Research Laboratory in Computer Science and its Applications) against the Coronavirus ! Learn more here.

« First ‹ Previous 1 2 3 4 Next › Last »